Stifel Nicolaus Trims Inventiva (NASDAQ:IVA) Target Price to $20.00

Inventiva (NASDAQ:IVA) had its target price reduced by Stifel Nicolaus from $25.00 to $20.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

Inventiva Price Performance

IVA stock opened at $1.84 on Thursday. Inventiva has a 52-week low of $1.53 and a 52-week high of $4.75. The company’s 50-day simple moving average is $2.25 and its 200-day simple moving average is $2.96.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.